Highlights
- •MOG-IgG was seronegative during both inflammatory events.
- •Seroconversion was transient and during interferon-beta treatment.
- •No disease progression was observed under interferon-beta therapy.
Abstract
Immunoglobulin G (IgG) autoantibodies targeting myelin oligodendrocyte glycoprotein
(MOG) have recently been associated with autoimmune CNS demyelination. We present
the case of a 35-year-old patient who was seronegative for MOG-IgG (as confirmed by
means of three independent immunoassays) during two corticosteroid-responsive attacks
of brainstem encephalitis and optic neuritis, respectively, but turned positive for
MOG-IgG under treatment with interferon-beta (IFN-beta), which was commenced 6 months
after onset of the first attack. MOG-IgG serum levels declined after therapy was switched
to glatiramer acetate. The fact that seroconversion was first observed under treatment
with IFN-beta is in accordance with previous evidence suggesting a role of IFN-beta
in disease exacerbation in antibody-mediated disorders.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases.Clinical immunology (Orlando, Fla.). 2011; 138: 247-254https://doi.org/10.1016/j.clim.2010.11.013
- Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease.Mult. Scler. 2015; 21: 866-874https://doi.org/10.1177/1352458514555785
- MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.J. Neuroinflammation. 2018; 15: 134https://doi.org/10.1186/s12974-018-1144-2
- MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.J. Neuroinflammation. 2016; 13: 280https://doi.org/10.1186/s12974-016-0718-0
- Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity.Brain : J. Neurol. 2008; 131: 1455-1463https://doi.org/10.1093/brain/awn077
- Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.Arch. Neurol. 2010; 67: 1016-1017https://doi.org/10.1001/archneurol.2010.188
- Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis.Neurology(R) Neuroimmunology & Neuroinflammation. 2016; 3: e257https://doi.org/10.1212/NXI.0000000000000257
- Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes.Ann Neurol. 2001; 50: 349-357https://doi.org/10.1002/ana.1096
Article info
Publication history
Published online: September 28, 2019
Accepted:
September 27,
2019
Received in revised form:
September 3,
2019
Received:
July 26,
2019
Identification
Copyright
© 2019 Elsevier B.V. All rights reserved.
